180 related articles for article (PubMed ID: 29581844)
1. Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Shimizu S; Tanabe K
Oncotarget; 2018 Mar; 9(18):14296-14305. PubMed ID: 29581844
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy.
Fukuda H; Takagi T; Kondo T; Yoshida K; Shimizu S; Nagashima Y; Tanabe K
Int J Clin Oncol; 2018 Jun; 23(3):539-546. PubMed ID: 29302841
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma.
Yamamoto Y; Matsuyama H; Matsumoto H; Sakano S; Fuji N; Oba K; Yamamoto M; Kamiryo Y; Hiragino T; Nagao K; Takai K; Aoki A
Jpn J Clin Oncol; 2020 Feb; 50(2):214-220. PubMed ID: 31755525
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the controlling nutritional status score in patients with metastatic renal cell carcinoma diagnosed before an era of first-line immune-oncology combination therapies.
Sekiya K; Ito M; Takemura K; Suzuki H; Kobayashi S; Koga F
Jpn J Clin Oncol; 2021 Oct; 51(10):1570-1576. PubMed ID: 34075403
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
Ramsey S; Lamb GW; Aitchison M; Graham J; McMillan DC
Cancer; 2007 Jan; 109(2):205-12. PubMed ID: 17149754
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
Taguchi S; Nakagawa T; Matsumoto A; Nagase Y; Kawai T; Tanaka Y; Yoshida K; Yamamoto S; Enomoto Y; Nose Y; Sato T; Ishikawa A; Uemura Y; Fujimura T; Fukuhara H; Kume H; Homma Y
Int J Urol; 2015 Jul; 22(7):638-43. PubMed ID: 25903328
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma.
Lucca I; de Martino M; Hofbauer SL; Zamani N; Shariat SF; Klatte T
World J Urol; 2015 Dec; 33(12):2045-52. PubMed ID: 25894368
[TBL] [Abstract][Full Text] [Related]
10. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio in predicting survival for patients with stage I-II gastric cancer.
Sun X; Liu X; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z
Chin J Cancer; 2016 Jun; 35(1):57. PubMed ID: 27342313
[TBL] [Abstract][Full Text] [Related]
11. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma.
Cho DS; Kim SI; Choo SH; Jang SH; Ahn HS; Kim SJ
Scand J Urol; 2016 Jun; 50(3):186-91. PubMed ID: 26878156
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model.
Gu L; Ma X; Wang L; Li H; Chen L; Li X; Zhang Y; Xie Y; Zhang X
Oncotarget; 2017 Aug; 8(32):52094-52103. PubMed ID: 28881716
[TBL] [Abstract][Full Text] [Related]
15. Glasgow prognostic score is superior to other inflammation-based scores in predicting survival of diffuse large B-cell lymphoma.
Hao X; Wei Y; Wei X; Zhou L; Wei Q; Zhang Y; Huang W; Feng R
Oncotarget; 2017 Sep; 8(44):76740-76748. PubMed ID: 29100345
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of preoperative lymphocyte to monocyte ratio in patients with nonmetastatic clear cell renal cell carcinoma.
Chang Y; Fu Q; Xu L; Zhou L; Liu Z; Yang Y; Lin Z; Xu J
Tumour Biol; 2016 Apr; 37(4):4613-20. PubMed ID: 26508025
[TBL] [Abstract][Full Text] [Related]
17. New prognostic model for synchronous metastatic renal cell carcinoma.
Naito S; Kato T; Ichiyanagi O; Narisawa T; Kurokawa M; Yagi M; Ushijima M; Ozawa M; Kanno H; Kurota Y; Fukuhara H; Kuboki Y; Yamagishi A; Sakurai T; Nishida H; Yamanobe T; Tsuchiya N
Int J Urol; 2020 May; 27(5):448-456. PubMed ID: 32207204
[TBL] [Abstract][Full Text] [Related]
18. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of inflammation-based prognostic scores in patients undergoing hepatobiliary resection for perihilar cholangiocarcinoma.
Okuno M; Ebata T; Yokoyama Y; Igami T; Sugawara G; Mizuno T; Yamaguchi J; Nagino M
J Gastroenterol; 2016 Feb; 51(2):153-61. PubMed ID: 26187429
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
